|
|
Article: Sheffield Pharmaceuticals Submits an Investigational New Drug Application For Budesonide Inhalation Suspension.
- Article from:
- PR Newswire
- Article date:
- April 4, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ST. LOUIS, April 4 /PRNewswire/ --
Sheffield Pharmaceuticals, Inc. (Amex: SHM) today announced that an Investigational New Drug Application (IND) has been submitted to the U.S. Food and Drug Administration for budesonide inhalation suspension for delivery via a standard commercial nebulizer. This IND will allow Sheffield to initiate clinical studies of this unit-dose packaged form of budesonide in the United States.
The budesonide inhalation product to be studied under this IND results from formulation work conducted by Sheffield's subsidiary, Respiratory Steroid Delivery, Ltd. (RSD). The formulation technology utilized was licensed by RSD from Elan ...